LAUSR.org creates dashboard-style pages of related content for over 1.5 million academic articles. Sign Up to like articles & get recommendations!

Outcome of a patient with refractory Hodgkin lymphoma on pembrolizumab, infected with SARS‐CoV‐2

Photo by nci from unsplash

A 22-year-old female presented the Emergency Department on the 14th March 2020 with a 3 day history of cough, pyrexia, sore throat, chills and rigors. Dyspnoea, myalgia, anosmia did not… Click to show full abstract

A 22-year-old female presented the Emergency Department on the 14th March 2020 with a 3 day history of cough, pyrexia, sore throat, chills and rigors. Dyspnoea, myalgia, anosmia did not feature at presentation. The patient had a history of early-stage unfavourable-risk, classical Hodgkin Lymphoma (HL) for which she was diagnosed in May 2017. She underwent two cycles of adriamycin/bleomycin/vinblastine/dacarbazine (ABVD) with escalation to bleomycin/etoposide/adriamycin/cyclophosphamide/vincristine/procarbazine/prednisolone (escBEACOPP) for four cycles due to a suboptimal response on interval positron emission tomography (PET) scan.

Keywords: patient refractory; lymphoma; hodgkin lymphoma; outcome patient; refractory hodgkin; lymphoma pembrolizumab

Journal Title: British Journal of Haematology
Year Published: 2020

Link to full text (if available)


Share on Social Media:                               Sign Up to like & get
recommendations!

Related content

More Information              News              Social Media              Video              Recommended



                Click one of the above tabs to view related content.